Previous close | 2.2300 |
Open | 2.2500 |
Bid | 2.1600 x 800 |
Ask | 2.3900 x 800 |
Day's range | 2.2300 - 2.2999 |
52-week range | 0.9550 - 3.5700 |
Volume | |
Avg. volume | 70,296 |
Market cap | 92.006M |
Beta (5Y monthly) | 2.13 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.6300 |
Earnings date | 08 Nov 2023 - 13 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.50 |
SOUTH SAN FRANCISCO, Calif., August 28, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET.
SOUTH SAN FRANCISCO, Calif., August 14, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates.
Spruce Biosciences, Inc. (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).